Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.56 |
| ▸ | CPB1 | P15086 | 3/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | CPA3 | P15088 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27667737 | 0.88 | CPB2 (0.56) | CPB2CPB1FOLH1CPA3 | |
| SCHEMBL4008975 | 0.82 | CPB2 (0.75) | CPB2FOLH1CPA3 | |
| SCHEMBL3091981 | 0.82 | CPB2 (0.59) | CPB2CPB1 | |
| SCHEMBL3091969 | 0.82 | CPB2 (0.59) | CPB2CPB1 | |
| SCHEMBL4008752 | 0.81 | CPB2 (0.51) | CPB2FOLH1CPA3 | |
| SCHEMBL4007106 | 0.76 | CPB2 (0.71) | CPB2CPB1FOLH1CPA3 | |
| SCHEMBL4005845 | 0.75 | CPB2 (0.55) | CPB2FOLH1CPA3 | |
| SCHEMBL7115699 | 0.73 | CPB2 (0.47) | CPB2CPB1 | |
| SCHEMBL2167204 | 0.72 | CPB2 (0.49) | CPB2CPB1 | |
| SCHEMBL7256270 | 0.72 | CPB2 (0.64) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1263739-C | Carboxypeptidase U inhibiting compounds, process for their preparation, pharmaceutical compositions containing them and their use | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | CN | claimed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | claimed |
| WO-2009082340-A1 | METHOD FOR MONITORING THE PROGRESSION OF FIBRINOLYSIS'646 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| CN-1263739-C | Carboxypeptidase U inhibiting compounds, process for their preparation, pharmaceutical compositions containing them and their use | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | CN | disclosed |
| US-7071175-B1 | Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| CN-1358174-A | New Compounds | ASTRAZENECA AB (SE) | 2002-07-10 | — | — | CN | disclosed |
| EP-1180098-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066557-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | BPGM, PLG, FGB | CPB2 47/4885CPB1 43/4885FOLH1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.